JP2022510736A - 大環状化合物とその使用 - Google Patents

大環状化合物とその使用 Download PDF

Info

Publication number
JP2022510736A
JP2022510736A JP2021554804A JP2021554804A JP2022510736A JP 2022510736 A JP2022510736 A JP 2022510736A JP 2021554804 A JP2021554804 A JP 2021554804A JP 2021554804 A JP2021554804 A JP 2021554804A JP 2022510736 A JP2022510736 A JP 2022510736A
Authority
JP
Japan
Prior art keywords
group
disease
methyl
mixture
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021554804A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022510736A5 (https=
JPWO2020116660A5 (https=
Inventor
重充 松本
亮磨 原
直義 野口
英人 福士
歩 新居田
聡 佐々木
実 生駒
俊威 小林
毅志 前川
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scohia Pharma Inc
Original Assignee
Scohia Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=70975488&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2022510736(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Scohia Pharma Inc filed Critical Scohia Pharma Inc
Publication of JP2022510736A publication Critical patent/JP2022510736A/ja
Publication of JP2022510736A5 publication Critical patent/JP2022510736A5/ja
Publication of JPWO2020116660A5 publication Critical patent/JPWO2020116660A5/ja
Priority to JP2024102161A priority Critical patent/JP2024123202A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2021554804A 2018-12-05 2019-12-04 大環状化合物とその使用 Pending JP2022510736A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024102161A JP2024123202A (ja) 2018-12-05 2024-06-25 大環状化合物とその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018228234 2018-12-05
JP2018228234 2018-12-05
PCT/JP2019/048593 WO2020116660A1 (en) 2018-12-05 2019-12-04 Macrocyclic compound and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024102161A Division JP2024123202A (ja) 2018-12-05 2024-06-25 大環状化合物とその使用

Publications (3)

Publication Number Publication Date
JP2022510736A true JP2022510736A (ja) 2022-01-27
JP2022510736A5 JP2022510736A5 (https=) 2022-11-30
JPWO2020116660A5 JPWO2020116660A5 (https=) 2022-11-30

Family

ID=70975488

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021554804A Pending JP2022510736A (ja) 2018-12-05 2019-12-04 大環状化合物とその使用
JP2024102161A Pending JP2024123202A (ja) 2018-12-05 2024-06-25 大環状化合物とその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024102161A Pending JP2024123202A (ja) 2018-12-05 2024-06-25 大環状化合物とその使用

Country Status (18)

Country Link
US (1) US11518763B2 (https=)
EP (1) EP3890738A4 (https=)
JP (2) JP2022510736A (https=)
KR (1) KR102919982B1 (https=)
CN (1) CN113164468A (https=)
AR (1) AR117251A1 (https=)
AU (1) AU2019391942B2 (https=)
BR (1) BR112021010704A2 (https=)
CA (1) CA3121952C (https=)
CL (1) CL2021001451A1 (https=)
CO (1) CO2021007304A2 (https=)
MX (1) MX2021006527A (https=)
NZ (1) NZ776102A (https=)
PH (1) PH12021551262A1 (https=)
SG (1) SG11202105125XA (https=)
TW (1) TWI820266B (https=)
UA (1) UA127872C2 (https=)
WO (1) WO2020116660A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3833662B1 (en) 2018-08-20 2024-01-17 Janssen Pharmaceutica NV Inhibitors of keap1-nrf2 protein-protein interaction
AU2020283361B2 (en) 2019-05-31 2025-11-27 Ube Corporation Benzotriazole derivative
CN116406364A (zh) * 2020-09-14 2023-07-07 赛诺菲公司 用于治疗红细胞障碍和炎性疾病的四氢异喹啉衍生物
KR20260005897A (ko) * 2023-04-03 2026-01-12 에이스링크 테라퓨틱스, 인코포레이티드 신규 화합물 및 이의 용도
CN119707895B (zh) * 2023-12-18 2026-03-31 江苏苏中药业研究院有限公司 一种7-甲酰基-2,3-二氢苯并呋喃-4-碳腈的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015092713A1 (en) * 2013-12-18 2015-06-25 Glaxosmithkline Intellectual Property Development Limited Nrf2 regulators
WO2018140876A1 (en) * 2017-01-30 2018-08-02 Biogen Ma Inc. Nrf2 activator
WO2018181345A1 (ja) * 2017-03-28 2018-10-04 武田薬品工業株式会社 複素環化合物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012028959A1 (en) 2010-08-31 2012-03-08 Pablo Villoslada Agonists of neurotrophin receptors and their use as medicaments
DK3492455T3 (da) 2013-06-21 2023-08-14 Karyopharm Therapeutics Inc 1,2,4-triazoler som nukleare transportmodulatorer og anvendelse til behandling af specifikke former for cancer
LT3307739T (lt) 2015-06-15 2021-03-10 Glaxosmithkline Intellectual Property Development Limited Nrf2 reguliatoriai
WO2016203401A1 (en) 2015-06-15 2016-12-22 Glaxosmithkline Intellectual Property Development Limited Nrf2 regulators
CA2988373A1 (en) 2015-06-15 2016-12-22 Glaxosmithkline Intellectual Property Development Limited Nrf2 regulators
US10201531B2 (en) 2015-08-12 2019-02-12 Mochida Pharmaceutical Co., Ltd. Indazolyl-oxo-isothiazole compounds
US10364256B2 (en) 2015-10-06 2019-07-30 Glaxosmithkline Intellectual Property Development Limited Biaryl pyrazoles as NRF2 regulators
US10351530B2 (en) 2015-10-06 2019-07-16 Glaxosmithkline Intellectual Property Development Limited Arylcyclohexyl pyrazoles as NRF2 regulators
JP2020500919A (ja) 2016-12-12 2020-01-16 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｎｒｆ２レギュレーターとしての３−カルボン酸ピロール
JP2020500918A (ja) 2016-12-12 2020-01-16 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｎｒｆ２レギュレーターとしてのｎ−アリールピラゾール
EP3555068B1 (en) 2016-12-14 2020-12-02 GlaxoSmithKline Intellectual Property Development Limited 3-oxo-1,4-diazepinyle compounds as nrf2 activators
ES2901617T3 (es) 2016-12-14 2022-03-23 Glaxosmithkline Ip Dev Ltd Bisarilamidas como reguladores de NRF2
US11117905B2 (en) 2016-12-14 2021-09-14 Glaxosmithkline Intellectual Property Development Limited Bisaryl heterocycles as NRF2 activators
CA3044773A1 (en) 2016-12-15 2018-06-21 Glaxosmithkline Intellectual Property Development Limited Nrf2 activators
JP2020502152A (ja) 2016-12-15 2020-01-23 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｎｒｆ２アクチベーターとしてのエーテル結合トリアゾール
UY37551A (es) 2016-12-27 2018-07-31 Biogen Ma Inc Activador de nrf2
US20190389830A1 (en) 2017-01-30 2019-12-26 Biogen Ma Inc. Nrf2 activator

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015092713A1 (en) * 2013-12-18 2015-06-25 Glaxosmithkline Intellectual Property Development Limited Nrf2 regulators
WO2018140876A1 (en) * 2017-01-30 2018-08-02 Biogen Ma Inc. Nrf2 activator
WO2018181345A1 (ja) * 2017-03-28 2018-10-04 武田薬品工業株式会社 複素環化合物

Also Published As

Publication number Publication date
EP3890738A4 (en) 2022-08-17
SG11202105125XA (en) 2021-06-29
US20220119391A1 (en) 2022-04-21
PH12021551262A1 (en) 2021-10-25
CA3121952C (en) 2025-05-13
TWI820266B (zh) 2023-11-01
WO2020116660A1 (en) 2020-06-11
AU2019391942A1 (en) 2021-06-03
CO2021007304A2 (es) 2021-06-21
TW202039494A (zh) 2020-11-01
JP2024123202A (ja) 2024-09-10
NZ776102A (en) 2024-12-20
CN113164468A (zh) 2021-07-23
MX2021006527A (es) 2021-07-21
AR117251A1 (es) 2021-07-21
AU2019391942B2 (en) 2024-03-21
CL2021001451A1 (es) 2021-12-24
UA127872C2 (uk) 2024-01-31
BR112021010704A2 (pt) 2021-08-24
KR20210099622A (ko) 2021-08-12
KR102919982B1 (ko) 2026-02-02
CA3121952A1 (en) 2020-06-11
US11518763B2 (en) 2022-12-06
EP3890738A1 (en) 2021-10-13

Similar Documents

Publication Publication Date Title
JP7253640B2 (ja) 複素環化合物およびその用途
US12595265B2 (en) Inhibitors of activin receptor-like kinase
JP7152369B2 (ja) 複素環化合物およびその用途
US11518763B2 (en) Macrocyclic compound and use thereof
JP7034941B2 (ja) Ｌｓｄ１／ｈｄａｃ二重阻害剤としてのシクロプロピル－アミド化合物
KR102050150B1 (ko) 융합-고리 화합물, 약학 조성물 및 이들의 용도
WO2018181345A1 (ja) 複素環化合物
CA3133753A1 (en) Novel small molecule inhibitors of tead transcription factors
JP7548814B2 (ja) Ｉｄｏ阻害剤および／またはｉｄｏ－ｈｄａｃ二重阻害剤としての多環式化合物
TW201702226A (zh) 尿素衍生物或其醫藥上可接受鹽
CA3180387A1 (en) Macrocyclic 2-amino-3-fluoro-but-3-enamides as inhibitors of mcl-1
CA3018358A1 (en) Pyridyl derivatives as bromodomain inhibitors
JP2022510874A (ja) ヒストンアセチラーゼｐ３００阻害剤及びその用途
JP2025512098A (ja) 複素環化合物
CA3018275A1 (en) Benzo[b]furans as bromodomain inhibitors
JP2025539434A (ja) 複素環化合物及びその用途
CN117321042A (zh) 用于治疗炎症性疾病或癌症的氧代二氢吲哚化合物
JP2021183587A (ja) 複素環化合物
RU2798235C9 (ru) Макроциклическое соединение и его применение
RU2798235C2 (ru) Макроциклическое соединение и его применение
TW202440081A (zh) σ-1受體拮抗劑及其應用
JP2026509885A (ja) マクロ環状複素環化合物及びその用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221121

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231226

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240507